Evidence map›Paper›PMID 33483287›Full record

ReviewBest practice & research. Clinical rheumatology2021

Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?

Bugra Han Egeli, Jeffrey A Sparks, Alfred H J Kim, Jean W Liew

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Best practice & research. Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. COVID-19's immuno-pathology and cardiovascular diseases.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Bugra Han EgeliGraduate Medical Sciences, Boston University School of Medicine, 72 E Concord St L-317, Boston, MA, 02118, USA. Electronic address: bhegeli@bu.edu.
Jeffrey A SparksDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, 60 Fenwood Road, #6016U, Boston, MA, 02115, USA. Electronic address: jsparks@bwh.harvard.edu.
Alfred H J KimDivision of Rheumatology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8045, St Louis, MO, 63110, USA. Electronic address: akim@dom.wustl.edu.
Jean W LiewSection of Rheumatology, Boston University School of Medicine, 650 Albany St, X200, Boston, MA, 02118, USA. Electronic address: jwliew@bu.edu.
Boston University · USBrigham and Women's Hospital · USWashington University in St. Louis · US

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
NIAMS NIH HHS P30 AR072577
6 · The paper itself

Abstract

A variety of treatment modalities have been investigated since the beginning of the Coronavirus Disease-19 (COVID-19) pandemic. The use of antimalarials (hydroxychloroquine and chloroquine) for COVID-19 treatment and prevention has proven to be a cautionary tale for widespread, off-label use of a medication during a crisis. The investigation of antimalarials for COVID-19 has also been a driver for a deluge of scientific output in a short amount of time. In this narrative review, we detail the evidence for and against antimalarial use in COVID-19, starting with the early small observational studies that influenced strategies worldwide. We then contrast these findings to later published larger observational studies and randomized controlled trials. We detail the emerging possible cardiovascular risks associated with antimalarial use in COVID-19 and whether COVID-19-related outcomes and cardiovascular risks may differ for antimalarials used in rheumatic diseases.

Indexed as

Antiviral AgentsCardiotoxicityCoronavirus InfectionsCOVID-19 Drug TreatmentHydroxychloroquineHumansSARS-CoV-2Antiviral AgentsHydroxychloroquineAntimalarialsChloroquineCoronavirusCOVID-19Hydroxychloroquine

Identifiers

PMID33483287
PMCPMC7775793
OpenAlexW3117694000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.